← Leaderboards
Ram I Mahato
University Of Nebraska Medical Center
$10,713,899
Attributed
$12,989,411
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,989,411 · 11
By mechanism
R01$12,971,411 · 9
R13$18,000 · 2
Top collaborators
- Donald Coulter5 shared
- Surinder Kumar Batra4 shared
- Natalia Aleksandr Osna3 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Donald Coulter$974,753
- Natalia Aleksandr Osna$4,604,885
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesApoptosisToxic EffectCellsPlayBiodistributionIn VivoDrug KineticsPharmaceutical PreparationsPathway InteractionsCombined Modality TherapyIn VitroDoseCancer Stem CellTumorChemotherapyNanomedicineMouse ModelErinaceidaeUptakeSmall MoleculeInnovationResistancePeptides
Grant awards (39)
Lipid nanomedicine targeting multiple signaling pathways of medulloblastoma$475,579
R01 · FY2025 · NS · contact PI
Nanomedicine of Hedgehog and AKT/ERK Dual Inhibitors for Pancreatic Cancer$442,114
R01 · FY2025 · CA · contact PI
Development and Preclinical Evaluation of Nanoformulations in Liver Fibrotic Mice$365,775
R01 · FY2025 · DK · contact PI
Overcoming Resistance Mechanisms in Hedgehog and Myc-amplified Medulloblastoma$360,639
R01 · FY2025 · NS · contact PI
Lipid nanomedicine targeting multiple signaling pathways of medulloblastoma$461,312
R01 · FY2024 · NS · contact PI
Nanomedicine of Hedgehog and AKT/ERK Dual Inhibitors for Pancreatic Cancer$420,006
R01 · FY2024 · CA · contact PI
Development and Preclinical Evaluation of Nanoformulations in Liver Fibrotic Mice$390,632
R01 · FY2024 · DK · contact PI
Overcoming Resistance Mechanisms in Hedgehog and Myc-amplified Medulloblastoma$388,690
R01 · FY2024 · NS · contact PI
Lipid nanomedicine targeting multiple signaling pathways of medulloblastoma$475,579
R01 · FY2023 · NS · contact PI
Nanomedicine of Hedgehog and AKT/ERK Dual Inhibitors for Pancreatic Cancer$433,269
R01 · FY2023 · CA · contact PI
Development and Preclinical Evaluation of Nanoformulations in Liver Fibrotic Mice$420,765
R01 · FY2023 · DK · contact PI
Overcoming Resistance Mechanisms in Hedgehog and Myc-amplified Medulloblastoma$400,709
R01 · FY2023 · NS · contact PI
Insight into the mechanism of action of the SSB interactome$311,852
R01 · FY2023 · GM · contact PI
Lipid nanomedicine targeting multiple signaling pathways of medulloblastoma$488,954
R01 · FY2022 · NS · contact PI
Nanomedicine of Hedgehog and AKT/ERK Dual Inhibitors for Pancreatic Cancer$454,747
R01 · FY2022 · CA · contact PI
Overcoming Resistance Mechanisms in Hedgehog and Myc-amplified Medulloblastoma$400,059
R01 · FY2022 · NS · contact PI
Overcoming Resistance Mechanisms in Hedgehog and Myc-amplified Medulloblastoma$399,408
R01 · FY2021 · NS · contact PI
Polymeric Nanomedicines of Hedgehog Inhibitor and miRNA for Treating Pancreatic Cancer$356,087
R01 · FY2018 · GM · contact PI
Polymeric Nanomedicines of Hedgehog Inhibitor and miRNA for Treating Pancreatic Cancer$356,087
R01 · FY2017 · GM · contact PI
Polymeric Nanomedicines of Small Molecules and miRNA for Treating Pancreatic Canc$338,594
R01 · FY2017 · EB · contact PI
Polymeric Nanomedicines of Hedgehog Inhibitor and miRNA for Treating Pancreatic Cancer$356,087
R01 · FY2016 · GM · contact PI
Polymeric Nanomedicines of Small Molecules and miRNA for Treating Pancreatic Canc$340,828
R01 · FY2016 · EB · contact PI
Research and Development of Nucleic Acid based Nanomedicines$10,000
R13 · FY2016 · EB · contact PI
Polymeric Nanomedicines of Hedgehog Inhibitor and miRNA for Treating Pancreatic Cancer$356,087
R01 · FY2015 · GM · contact PI
Polymeric Nanomedicines of Small Molecules and miRNA for Treating Pancreatic Canc$336,360
R01 · FY2015 · EB · contact PI
Research and Development of Novel Drug Delivery Systems Symposium$8,000
R13 · FY2015 · EB · contact PI
Polymeric Nanomedicines of Small Molecules and miRNA for Treating Pancreatic Canc$343,092
R01 · FY2014 · EB · contact PI
Growth Factor and Antiapoptotic Gene Delivery to Human Islets$283,945
R01 · FY2012 · DK · contact PI
Growth Factor and Antiapoptotic Gene Delivery to Human Islets$283,945
R01 · FY2011 · DK · contact PI
Growth Factor and Antiapoptotic Gene Delivery to Human Islets$316,483
R01 · FY2010 · DK · contact PI
Targeted Delivery of TFOs for Treatment of Liver Fibrosis$223,098
R01 · FY2010 · EB · contact PI
Growth Factor and Antiapoptotic Gene Delivery to Human Islets$319,680
R01 · FY2009 · DK · contact PI
Targeted Delivery of TFOs for Treatment of Liver Fibrosis$225,351
R01 · FY2009 · EB · contact PI
Growth Factor and Antiapoptotic Gene Delivery to Human Islets$238,771
R01 · FY2008 · DK · contact PI
Targeted Delivery of TFOs for Treatment of Liver Fibrosis$225,351
R01 · FY2008 · EB · contact PI
Growth Factor and Antiapoptotic Gene Delivery to Human Islets$243,645
R01 · FY2007 · DK · contact PI
Targeted Delivery of TFOs for Treatment of Liver Fibrosis$229,950
R01 · FY2007 · EB · contact PI
Growth Factor and Antiapoptotic Gene Delivery to Human Islets$250,921
R01 · FY2006 · DK · contact PI
Growth Factor and Antiapoptotic Gene Delivery to Human Islets$256,960
R01 · FY2005 · DK